NO20005259L - Fremgangsmåte for fremstilling av enantiomerrent N-metyl-N- [(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)etyl]-2,2- difenylacetamid - Google Patents

Fremgangsmåte for fremstilling av enantiomerrent N-metyl-N- [(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)etyl]-2,2- difenylacetamid

Info

Publication number
NO20005259L
NO20005259L NO20005259A NO20005259A NO20005259L NO 20005259 L NO20005259 L NO 20005259L NO 20005259 A NO20005259 A NO 20005259A NO 20005259 A NO20005259 A NO 20005259A NO 20005259 L NO20005259 L NO 20005259L
Authority
NO
Norway
Prior art keywords
diphenylacetamide
hydroxypyrrolidin
phenyl
ethyl
methyl
Prior art date
Application number
NO20005259A
Other languages
English (en)
Other versions
NO20005259D0 (no
NO317984B1 (no
Inventor
Andreas Bathe
Bernd Helfert
Karl-August Ackermann
Rudolf Gottschlich
Ingeborg Stein
Jens Budak
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7865063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20005259(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20005259D0 publication Critical patent/NO20005259D0/no
Publication of NO20005259L publication Critical patent/NO20005259L/no
Publication of NO317984B1 publication Critical patent/NO317984B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B35/00Reactions without formation or introduction of functional groups containing hetero atoms, involving a change in the type of bonding between two carbon atoms already directly linked
    • C07B35/02Reduction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00Formation or introduction of functional groups containing nitrogen
    • C07B43/06Formation or introduction of functional groups containing nitrogen of amide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20005259A 1998-04-20 2000-10-19 Fremgangsmate for fremstilling av enantiomerrent N-metyl-N-[(1S eller 1R)-1-fenyl-2-((3S eller 3R)-3-hydroksypyrrolidin-1-yl)etyl]-2,2-difenylacetamid, med anvendelse av (1S,3S)-enantiomeren til fremstilling av et farmasoytisk preparat NO317984B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19817393 1998-04-20
DE19827633A DE19827633A1 (de) 1998-04-20 1998-06-20 Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
PCT/EP1999/002574 WO1999054298A1 (de) 1998-04-20 1999-04-16 Verfahren zur herstellung von enantiomerenreinem n-methyl- n-[(1s)- 1-phenyl- 2-((3s)-3- hydroxypyrrolidin- 1-yl)ethyl]- 2,2- diphenylacetamid

Publications (3)

Publication Number Publication Date
NO20005259D0 NO20005259D0 (no) 2000-10-19
NO20005259L true NO20005259L (no) 2000-10-19
NO317984B1 NO317984B1 (no) 2005-01-17

Family

ID=7865063

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005259A NO317984B1 (no) 1998-04-20 2000-10-19 Fremgangsmate for fremstilling av enantiomerrent N-metyl-N-[(1S eller 1R)-1-fenyl-2-((3S eller 3R)-3-hydroksypyrrolidin-1-yl)etyl]-2,2-difenylacetamid, med anvendelse av (1S,3S)-enantiomeren til fremstilling av et farmasoytisk preparat

Country Status (27)

Country Link
US (1) US6344566B1 (no)
EP (2) EP1073634B1 (no)
JP (1) JP4688292B2 (no)
KR (1) KR100649175B1 (no)
CN (2) CN1846696A (no)
AR (2) AR019080A1 (no)
AT (2) ATE303361T1 (no)
AU (2) AU761721B2 (no)
BR (1) BR9909731A (no)
CA (1) CA2329210C (no)
CY (1) CY1112314T1 (no)
CZ (1) CZ301121B6 (no)
DE (2) DE19827633A1 (no)
DK (2) DK1607090T3 (no)
ES (2) ES2375384T3 (no)
HU (1) HUP0101600A3 (no)
MY (1) MY120471A (no)
NO (1) NO317984B1 (no)
PL (1) PL206969B1 (no)
PT (1) PT1607090E (no)
RU (1) RU2298549C2 (no)
SI (2) SI1607090T1 (no)
SK (2) SK286442B6 (no)
TW (1) TWI249524B (no)
UA (1) UA73472C2 (no)
WO (1) WO1999054298A1 (no)
ZA (1) ZA200006689B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
JP2007509865A (ja) * 2003-10-30 2007-04-19 ティオガ ファーマシュウティカルズ,インコーポレイテッド 神経障害の治療における選択的オピエート受容体調節物質の使用
US20070160559A1 (en) * 2006-01-12 2007-07-12 Roszell James A Skin disinfectant composition and methods for using
RU2441655C2 (ru) * 2007-03-30 2012-02-10 Тиога Фармасьютикалз Инк. Агонисты каппа-опиоидов для лечения синдрома раздраженного кишечника с преобладанием диареи и перемежающегося синдрома раздраженного кишечника
CN103664727A (zh) * 2013-12-19 2014-03-26 无锡万全医药技术有限公司 一种一锅法制备1-[(3s)-3-羟基吡咯烷-1-基]-(2s)-2-甲氨基-2-苯基乙烷的工艺
CN103772257A (zh) * 2013-12-31 2014-05-07 无锡万全医药技术有限公司 一种制备2-((3s)-3-羟基吡咯烷-1-基)-(1s)-1-苯乙基氨基甲酸酯的方法
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
CN112574068A (zh) * 2020-11-17 2021-03-30 万华化学(宁波)有限公司 一种低色号高稳定性碳化二亚胺改性异氰酸酯的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4034785A1 (de) * 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4425071C2 (de) * 1994-07-15 1996-08-29 Degussa Verfahren zur Herstellung optisch aktiver Pyrrolidine mit hoher Enantiomerenreinheit
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) * 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
WO1998003491A1 (en) * 1996-07-24 1998-01-29 Warner-Lambert Company Diphenyl-cyclopropenes as selective k-agonists
DE19647538A1 (de) * 1996-11-16 1998-05-20 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[1-phenyl-2-(-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid

Also Published As

Publication number Publication date
SK15572000A3 (sk) 2001-05-10
AU2003248428A1 (en) 2003-11-06
CZ301121B6 (cs) 2009-11-11
JP4688292B2 (ja) 2011-05-25
HUP0101600A3 (en) 2002-12-28
CZ20003860A3 (cs) 2001-01-17
ES2251194T3 (es) 2006-04-16
CA2329210A1 (en) 1999-10-28
TWI249524B (en) 2006-02-21
ZA200006689B (en) 2002-02-18
AR019080A1 (es) 2001-12-26
PL206969B1 (pl) 2010-10-29
EP1073634A1 (de) 2001-02-07
DE19827633A1 (de) 1999-10-21
BR9909731A (pt) 2000-12-19
CN1297435A (zh) 2001-05-30
MY120471A (en) 2005-10-31
UA73472C2 (en) 2005-08-15
PL343556A1 (en) 2001-08-27
HUP0101600A2 (hu) 2001-09-28
DE59912502D1 (de) 2005-10-06
AU761721B2 (en) 2003-06-05
SK286442B6 (sk) 2008-10-07
KR20010042750A (ko) 2001-05-25
EP1607090A1 (de) 2005-12-21
NO20005259D0 (no) 2000-10-19
AR066455A2 (es) 2009-08-19
JP2002512223A (ja) 2002-04-23
PT1607090E (pt) 2012-01-10
CA2329210C (en) 2008-03-04
DK1607090T3 (da) 2012-01-30
HK1039111A1 (en) 2002-04-12
CY1112314T1 (el) 2015-12-09
ATE527999T1 (de) 2011-10-15
EP1073634B1 (de) 2005-08-31
NO317984B1 (no) 2005-01-17
RU2298549C2 (ru) 2007-05-10
KR100649175B1 (ko) 2006-11-24
DK1073634T3 (da) 2006-01-09
ATE303361T1 (de) 2005-09-15
SI1073634T1 (sl) 2006-02-28
ES2375384T3 (es) 2012-02-29
US6344566B1 (en) 2002-02-05
WO1999054298A1 (de) 1999-10-28
AU4031199A (en) 1999-11-08
SI1607090T1 (sl) 2012-01-31
CN1846696A (zh) 2006-10-18
SK288016B6 (sk) 2012-11-05
EP1607090B1 (de) 2011-10-12
CN1310884C (zh) 2007-04-18
AU2003248428B2 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
HUP0101434A3 (en) Sulfonamide-containing indole compounds, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same
NO20006630D0 (no) Farmasöytisk sammensetning for behandlingen av diabetes
HUP0105480A3 (en) Benzofuran derivatives, process for preparation of the same and uses thereof
NO20022087L (no) Fremgangsmåte for behandling av diabetes
AU2001292480A1 (en) Novel pyridazine compounds for the treatment of diabetes
AU2000276362A1 (en) Composition for the treatment of diabetes
NO20005259L (no) Fremgangsmåte for fremstilling av enantiomerrent N-metyl-N- [(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)etyl]-2,2- difenylacetamid
AU6432800A (en) Process for the synthesis of citalopram
NO963526D0 (no) N-metyl-N-[(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)-etylÅ-2,2-difenylacetamid
AU2002256053A1 (en) Novel bgp compounds for therapy and diagnosis and methods for using same
EG24052A (en) Novel processes for the preparation of (r)-a (2,3-demethoxyphenyl-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethapnol
HUP0201135A3 (en) Substituted benzolactam compounds, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them
EE200400016A (et) Protsess 1,5-diarüül-3-trifluorometüül-delta²-pürasoliinide ratseemiliste ja enantiomeerselt puhaste derivaatide valmistamiseks
AU2003244235A1 (en) Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for the synthesis thereof and process for preparation of the intermediates
AU2129800A (en) Improved process for the preparation of benzenesulfonylureas as oral hypoglycemic agents of the second generation
AU1299700A (en) Blood plasma replacement solution
AU2440599A (en) Therapeutic agent for complication of diabetes
AU2003272967A1 (en) Processes for producing optically active n-(2,3-epoxypropan-1-yl)phthalimide
AU5514199A (en) Process for the preparation of 2-(aryloxymethyl)-2,5,7,8-tetramethylchroman-6-ols
AU2002232117A1 (en) Process for the preparation of ethyl 2, 3-dihydrobenzo(1,4)dioxin-2-carboxylate
AU3985299A (en) Improved process for the preparation of trifluoromethyl containing derivatives
GB2399569B (en) "Process for the Preparation of Ethyl 2, 3-Dihydrobenzo [1,4]Dioxin-2-Carboxylate"
SG63714A1 (en) Process for the preparation of 5-(alkoxmethyl)-2, 3-pyridinedicarboximide compounds
AU4475300A (en) Tetrahydroisoquinolinyl-indole derivatives for the treatment of depression
PL370743A1 (en) Process for the preparation of ethyl 2,3-dihydrobenzo[1,4]dioxin-2-carboxylate

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees